Ironwood Pharmaceuticals - IRWD Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.40
  • Forecasted Upside: 203.63%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$6.06
▼ -0.43 (-6.63%)

This chart shows the closing price for IRWD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ironwood Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IRWD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IRWD

Analyst Price Target is $18.40
▲ +203.63% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Ironwood Pharmaceuticals in the last 3 months. The average price target is $18.40, with a high forecast of $22.00 and a low forecast of $14.00. The average price target represents a 203.63% upside from the last price of $6.06.

This chart shows the closing price for IRWD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Ironwood Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/29/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/23/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2024Craig HallumLower TargetBuy ➝ Buy$18.00 ➝ $14.00Low
3/1/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$20.00 ➝ $14.00Low
2/16/2024Piper SandlerBoost TargetOverweight ➝ Overweight$20.00 ➝ $21.00Low
1/17/2024Craig HallumInitiated CoverageBuy$21.00Low
12/14/2023Wells Fargo & CompanyInitiated CoverageOverweight$20.00Low
11/9/2023Jefferies Financial GroupInitiated CoverageBuy$21.00Low
9/28/2023JMP SecuritiesInitiated CoverageOutperform$22.00Low
5/23/2023Piper SandlerBoost Target$16.00 ➝ $19.00Low
9/2/2022Capital One FinancialInitiated CoverageOverweight$15.00Low
8/16/2022Wells Fargo & CompanyBoost TargetEqual Weight$12.00 ➝ $13.00Low
4/22/2022Piper SandlerInitiated CoverageOverweight$16.00High
10/12/2021Morgan StanleyBoost TargetEqual Weight$13.00 ➝ $14.00Low
7/16/2021Morgan StanleyBoost TargetEqual Weight$11.00 ➝ $12.00Low
7/6/2021Northland SecuritiesReiterated RatingBuy$15.00Medium
2/25/2021Morgan StanleyLower TargetEqual Weight$12.00 ➝ $11.00High
11/6/2020Credit Suisse GroupBoost TargetNeutral$11.00 ➝ $12.00High
11/6/2020Morgan StanleyBoost TargetEqual Weight$11.00 ➝ $12.00Medium
9/30/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$14.00 ➝ $9.00High
8/7/2020Morgan StanleyBoost TargetEqual Weight$10.00 ➝ $11.00Low
8/3/2020Northland SecuritiesReiterated RatingBuyHigh
7/15/2020Morgan StanleyLower TargetEqual Weight$11.00 ➝ $10.00Low
6/17/2020Northland SecuritiesInitiated CoverageOutperform$14.00High
6/1/2020Credit Suisse GroupLower TargetNeutral$12.00 ➝ $11.00Low
5/11/2020HC WainwrightLower TargetNeutral$13.00 ➝ $11.00High
5/7/2020Credit Suisse GroupReiterated RatingHold$12.00Low
5/7/2020Morgan StanleyLower TargetEqual Weight$12.00 ➝ $11.00Low
4/30/2020Wells Fargo & CompanyLower TargetOverweight$16.00 ➝ $15.00Medium
4/15/2020Morgan StanleyLower TargetEqual Weight$13.00 ➝ $12.00High
1/28/2020HC WainwrightReiterated RatingHold$13.00Low
1/21/2020HC WainwrightReiterated RatingHold$13.00Low
9/13/2019CowenSet TargetHold$12.00Low
7/31/2019WedbushBoost TargetNeutral$11.00 ➝ $12.00High
7/10/2019Credit Suisse GroupReiterated RatingNeutralLow
6/24/2019HC WainwrightSet TargetHold$13.00Low
(Data available from 5/23/2019 forward)

News Sentiment Rating

0.47 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/26/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/25/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/25/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/24/2024
  • 21 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/23/2024
  • 15 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
3/24/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/23/2024
  • 12 very positive mentions
  • 13 positive mentions
  • 4 negative mentions
  • 3 very negative mentions
5/23/2024

Current Sentiment

  • 12 very positive mentions
  • 13 positive mentions
  • 4 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Ironwood Pharmaceuticals logo
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $6.06
Low: $6.04
High: $6.50

50 Day Range

MA: $7.93
Low: $6.42
High: $9.11

52 Week Range

Now: $6.06
Low: $6.04
High: $15.70

Volume

2,611,993 shs

Average Volume

4,056,365 shs

Market Capitalization

$948.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Ironwood Pharmaceuticals?

The following equities research analysts have issued reports on Ironwood Pharmaceuticals in the last twelve months: Craig Hallum, Jefferies Financial Group Inc., JMP Securities, Piper Sandler, StockNews.com, TheStreet, and Wells Fargo & Company.
View the latest analyst ratings for IRWD.

What is the current price target for Ironwood Pharmaceuticals?

5 Wall Street analysts have set twelve-month price targets for Ironwood Pharmaceuticals in the last year. Their average twelve-month price target is $18.40, suggesting a possible upside of 183.5%. JMP Securities has the highest price target set, predicting IRWD will reach $22.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $14.00 for Ironwood Pharmaceuticals in the next year.
View the latest price targets for IRWD.

What is the current consensus analyst rating for Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IRWD will outperform the market and that investors should add to their positions of Ironwood Pharmaceuticals.
View the latest ratings for IRWD.

What other companies compete with Ironwood Pharmaceuticals?

Other companies that are similar to Ironwood Pharmaceuticals include Innoviva, OPKO Health, MannKind, Dynavax Technologies and Cryoport. Learn More about companies similar to Ironwood Pharmaceuticals.

How do I contact Ironwood Pharmaceuticals' investor relations team?

Ironwood Pharmaceuticals' physical mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The biotechnology company's listed phone number is (617) 621-7722 and its investor relations email address is [email protected]. The official website for Ironwood Pharmaceuticals is www.ironwoodpharma.com. Learn More about contacing Ironwood Pharmaceuticals investor relations.